公开(公告)号：US20190142971A1

公开(公告)日：2019-05-16

申请号：US16050845

申请日：2018-07-31

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Örn Almarsson ,  David D. Hile ,  Ciáran Lawlor ,  John Podobinski ,  Staci Sabnis ,  Antonin De Fougerolles ,  Divakar Ramakrishnan ,  Kristy M. Wood

IPC: A61K48/00 ,  A61K47/52 ,  C12N15/88 ,  C12N15/87

Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.

公开(公告)号：US20180086816A1

公开(公告)日：2018-03-29

申请号：US15591820

申请日：2017-05-10

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  Eric Yi-Chun Huang ,  Tirtha Chakraborty ,  Sayda M. Elbashir

IPC: C07K14/76 ,  C07K14/61 ,  C07K14/50 ,  C07K14/535 ,  C07K14/59 ,  C07K14/605 ,  C12N15/67 ,  C07K14/765 ,  C07K16/00

CPC classification number: C07K14/76 ,  A61K48/00 ,  C07K14/50 ,  C07K14/535 ,  C07K14/59 ,  C07K14/605 ,  C07K14/61 ,  C07K14/765 ,  C07K16/00 ,  C07K2319/00 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20180009866A1

公开(公告)日：2018-01-11

申请号：US15656740

申请日：2017-07-21

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  William Joseph Issa ,  Edward John Miracco ,  Jennifer Nelson ,  John Reynders ,  Matthew Stanton

IPC: C07K14/535 ,  C07K14/505 ,  C12N9/02 ,  C12P19/34

CPC classification number: C07K14/535 ,  A61K48/005 ,  C07K14/505 ,  C12N9/0069 ,  C12P19/34 ,  C12P21/02 ,  C12Y113/12007

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.